ArticleJournal of hypertension2012
Microalbuminuria breakthrough under chronic renin-angiotensin-aldosterone system suppression.
Article in Journal of hypertension, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03887416 (Effect of Dapagliflozin on Nighttime Blood Pressure in Type 2 Diabetes), which is not on this map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effect of Dapagliflozin on Nighttime Blood Pressure in Type 2 Diabetes
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis.BMC nephrology · 2016Pooled it
- Efficacy of single-pill perindopril/indapamide in patients with hypertension and type 2 diabetes.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2014Trial
- ABCDE to identify and prevent chronic kidney disease: a call to action.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2025Article
- TCA Cycle and Fatty Acids Oxidation Reflect Early Cardiorenal Damage in Normoalbuminuric Subjects with Controlled Hypertension.Antioxidants (Basel, Switzerland) · 2021Article
- Long-Term Effects of Spironolactone on Kidney Function and Hyperkalemia-Associated Hospitalization in Patients with Chronic Kidney Disease.Journal of clinical medicine · 2018Article
- Immune system deregulation in hypertensive patients chronically RAS suppressed developing albuminuria.Scientific reports · 2017Article
- Urinary exosomes reveal protein signatures in hypertensive patients with albuminuria.Oncotarget · 2017Article
- Kalirin and CHD7: novel endothelial dysfunction indicators in circulating extracellular vesicles from hypertensive patients with albuminuria.Oncotarget · 2017Article
- Urinary alpha-1 antitrypsin and CD59 glycoprotein predict albuminuria development in hypertensive patients under chronic renin-angiotensin system suppression.Cardiovascular diabetology · 2016Article
- Genetic predisposition to albuminuria is associated with increased arterial stiffness: role of elastin.British journal of pharmacology · 2015Article
- The necessity and effectiveness of mineralocorticoid receptor antagonist in the treatment of diabetic nephropathy.Hypertension research : official journal of the Japanese Society of Hypertension · 2015Review
- Renin-angiotensin system blockade: time for a reappraisal?European heart journal · 2014Article
Corrections and comments
- Commented on by
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesMicroalbuminuria has been shown to be a potent predictor for future development of cardiovascular and renal events that can be prevented by the use of angiotensin-converting enzyme inhibitors (ACEis) or angiotensin receptor blockers (ARBs). Both classes of drugs are now-a-days widely used in the treatment of arterial hypertension since the very early stages of the cardiorenal continuum when only cardiovascular risk factors are detected. We describe here the development of de-novo microalbuminuria in patients chronically treated with either an ACEi or an ARB at adequate doses.
methodsWe reviewed the evolution of 1433 patients (mean age 60.5 ± 12.4 years, 50.3% men, 6.6% having type 2 diabetes), arriving in our hospital-based Hypertension Unit previously treated for a least 2 years either with an ACEi or an ARB, at adequate doses, alone or in combination with other antihypertensive drugs.
resultsA total of 184 (16.1%) patients developed new-onset microalbuminuria, whereas macroalbuminuria was detected in 11 (1.0%) patients at the end of follow-up. Albuminuria appeared at any level of blood pressure (BP) from below 130/80 mmHg, albeit the highest percentage was seen when SBP was above 160 mmHg. De-novo microalbuminuria was more frequent in those patients presenting with established cardiovascular disease and predicts the future development of cardiovascular events but was not accompanied by a significant worsening of renal function.
conclusionThese data indicate that a reappraisal of renin-angiotensin-aldosterone system (RAAS) suppression is required when microalbuminuria appears in patients under chronic RAAS suppression.
Indexed as
Identifiers
22080225What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.